• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Secondary Antibiotic Prophylaxis Reduces Rheumatic Heart Disease Progression

byDavid XiangandHarsh Shah
January 24, 2022
in Cardiology, Chronic Disease, Infectious Disease, Rheumatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with latent rheumatic heart disease, secondary antibiotic prophylaxis reduced the risk of rheumatic heart disease progression.

2. Secondary antibiotic prophylaxis did not significantly reduce the risk of rheumatic heart disease regression.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Rheumatic heart disease is a chronic valvular heart disease that affects more than 40.5 million people worldwide and causes approximately 306,000 deaths annually. Secondary antibiotic prophylaxis with intramuscular penicillin G benzathine is used in the management of rheumatic fever, but there is a gap in knowledge as to understanding its effectiveness in improving outcomes for children and adolescents with latent rheumatic heart disease, especially in low-resource settings. This study found that secondary antibiotic prophylaxis provided a significantly reduced risk of rheumatic heart disease progression. This study was limited by lack of applicability to a real-world setting such as lack of retention in care, availability of medication, social stigma, and limited understanding of the disease. Nevertheless, these study’s findings are significant, as they demonstrate that secondary antibiotic prophylaxis significantly reduced the risk of latent rheumatic heart disease progression in children and adolescents.

Click to read the study in NEJM

Relevant Reading: Native-Valve Infective Endocarditis

In-Depth [randomized control trial]: This randomized control trial included 799 patients age 5 to 17 years from the Gulu District of Uganda, with 399 in the prophylaxis group and 400 in the control group. Patients with a new diagnosis of latent rheumatic heart disease were eligible. Patients who had moderate or severe disease, prior history of rheumatic fever or structural heart disease, or who had known penicillin allergy were excluded from the study. Patients in the prophylaxis group received IM penicillin G benzathine every 4 weeks for 2 years, while participants in the control group received no prophylaxis and no placebo. The primary outcome measured was the echocardiographic progression of latent rheumatic heart disease at 2 years. Outcomes in the primary analysis were assessed via the 2012 World Heart Federation criteria and a four-member consensus panel evaluated and classified the echocardiograms, with a generalized linear model with an identity link and binomial distribution conducted for statistical analysis. Between the two treatment groups, 3 participants (0.8%) receiving antibiotic prophylaxis demonstrated echocardiographic progression at 2 years, as compared with 33 (8.2%) in the control group (risk difference, −7.5%; 95% confidence interval [CI], −10.2 to −4.7). Regarding disease regression, 195 participants (48.9%) receiving antibiotic prophylaxis 191 participants (47.8%) in the control group had echocardiographic regression of latent rheumatic heart disease at 2 years (risk difference, 1.5%; 95% CI, −5.4 to 8.4). Overall, this study demonstrated that secondary antibiotic prophylaxis significantly reduced the risk of latent rheumatic heart disease progression in children and adolescents.

RELATED REPORTS

#VisualAbstract: Immediate Transfusion in African Children with Uncomplicated Severe Anemia

The TRACT trial: no mortality benefit observed in African children with uncomplicated severe anemia who receive transfusion

Chest pain may be better than EKG, echo for predicting coronary artery disease prognosis

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: benzathineechocardiographypenicillin Grheumatic heart diseaseUganda
Previous Post

Oral microbiome therapy reduced Clostridioides difficile recurrence

Next Post

Endometriosis associated with early natural menopause

RelatedReports

#VisualAbstract: Immediate Transfusion in African Children with Uncomplicated Severe Anemia
StudyGraphics

#VisualAbstract: Immediate Transfusion in African Children with Uncomplicated Severe Anemia

September 4, 2019
Ticagrelor reversal agent provides immediate and sustained effect
Chronic Disease

The TRACT trial: no mortality benefit observed in African children with uncomplicated severe anemia who receive transfusion

August 2, 2019
Chest pain may be better than EKG, echo for predicting coronary artery disease prognosis
Cardiology

Chest pain may be better than EKG, echo for predicting coronary artery disease prognosis

August 11, 2014
Echocardiographic screening does not improve all-cause mortality
Cardiology

Echocardiographic screening does not improve all-cause mortality

July 24, 2013
Next Post
Early language exposure is predictive of language skills and IQ in school-age children

Endometriosis associated with early natural menopause

Intentional injuries leading to ED visits often occur at school

Later start times may be preferred by secondary school teachers

Balanced-multi-electrolyte-solution does not reduce risk of death among intensive care patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
  • #VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.